Scholar Rock Holding Corp (SRRK) Wednesday reported positive results from the Phase 2 EMBRAZE study of apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
The EMBRAZE study was designed to evaluate apitegromab in adults with obesity while receiving tirzepatide. In the study, patients receiving apitegromab with tirzepatide showed a 54.9% preservation of lean mass compared to those who received tirzepatide alone. Patients who received apitegramab with tirsepatide lost 18.8 pounds of fat over 24 weeks, compared to 17.7 pounds of fat loss in those who received tirsepatide alone. Further, Apitegromab with tirzepatide was generally well tolerated by participants.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.